Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Syntara
The early and late asthmatic response were both significantly attenuated by the highest dose of ASM8. The methacholine challenge and other parameters (ECP, mRNA knockdown on CCR3 and B-Chain of IL-3-Il-5 and GMCSF were attenuated by ASM8.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Men and women 18 to 65 years of age
Generally good health; steroid naïve (or who have not taken inhaled/oral corticosteroid within last month) mild to moderate, stable, allergic asthma as defined by ATS criteria
History of episodic wheeze and shortness of breath
Forced expiratory volume in one second (FEV1) at baseline ≥ 70% of the predicted value
Able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.
You may not be if
Significant acute or chronic medical or psychiatric illness
Known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks
Use of inhaled or oral corticosteroids within the last 30 days, or need for antihistamines within 72 hours of each allergen or methacholine challenge, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed).
Clareo Health | Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma
